InsiderTrades.com logo
Top "Sleeping Giant" Crypto In The Market Now
From Crypto 101 Media   |   Ad
Top "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your financial future.
Click here to discover our #1 crypto pick before it's too late
Steven Gannon net worth and biography
  • Phone
  • Email
  • Website

Steven Gannon Biography and Net Worth

Director of Fusion Pharmaceuticals

Mr. Gannon was most recently Chief Financial Officer, Senior Vice President of Finance and Treasurer at Aptalis Pharma Inc., until it was acquired by Forest Laboratories Inc. Prior to joining Aptalis, Mr. Gannon served as Chief Financial Officer for Cryocath Technologies Inc., which was acquired by Medtronic Inc. Prior to Cryocath, Mr. Gannon served as Head of Finance and Administration of the research division of AstraZeneca Canada Inc. and Chief Financial Officer of Mallinckrodt Medical Inc.'s Canadian operations.

Mr. Gannon currently serves on the Boards of Directors and as Chairman of the Audit Committees of Aerogen, enGene Inc., and LABORIE Medical Technologies, and on the Board of Directors and as a member of the Audit Committee of Xenon Pharmaceuticals. Previously, he served on the Board of Directors of Advanced Accelerator Applications SA. He received a bachelor of commerce from Concordia University in Montreal and completed the Executive Program at the Richard Ivey School of Business at the University of Western Ontario. Mr. Gannon is a Certified Public Accountant (CPA) and Chartered Accountant (CA).

What is Steven Gannon's net worth?

The estimated net worth of Steven Gannon is at least $43,100.00 as of March 7th, 2024. Mr. Gannon owns 2,000 shares of Fusion Pharmaceuticals stock worth more than $43,100 as of November 13th. This net worth estimate does not reflect any other investments that Mr. Gannon may own. Learn More about Steven Gannon's net worth.

How do I contact Steven Gannon?

The corporate mailing address for Mr. Gannon and other Fusion Pharmaceuticals executives is 270 LONGWOOD ROAD SOUTH, HAMILTON A6, L8P 0A6. Fusion Pharmaceuticals can also be reached via phone at 289-799-0891 and via email at [email protected]. Learn More on Steven Gannon's contact information.

Has Steven Gannon been buying or selling shares of Fusion Pharmaceuticals?

Steven Gannon has not been actively trading shares of Fusion Pharmaceuticals during the last quarter. Most recently, on Thursday, August 11th, Steven Gannon bought 44,400 shares of Fusion Pharmaceuticals stock. The stock was acquired at an average cost of $2.03 per share, with a total value of $90,132.00. Following the completion of the transaction, the director now directly owns 56,400 shares of the company's stock, valued at $114,492. Learn More on Steven Gannon's trading history.

Who are Fusion Pharmaceuticals' active insiders?

Fusion Pharmaceuticals' insider roster includes Steven Gannon (Director), and John Valliant (CEO). Learn More on Fusion Pharmaceuticals' active insiders.

Steven Gannon Insider Trading History at Fusion Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/11/2022Buy44,400$2.03$90,132.0056,400View SEC Filing Icon  
8/23/2021Buy2,829$7.99$22,603.7112,000View SEC Filing Icon  
8/16/2021Buy6,000$8.10$48,600.006,000View SEC Filing Icon  
See Full Table

Steven Gannon Buying and Selling Activity at Fusion Pharmaceuticals

This chart shows Steven Gannon's buying and selling at Fusion Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Fusion Pharmaceuticals Company Overview

Fusion Pharmaceuticals logo
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor. It is conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, the company develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers.; FPI-2068, a bispecific antibody, which is in Phase 1 clinical trial targeting epidermal growth factor receptor, and mesenchymal epithelial transition factor. It has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The company was incorporated in 2014 and is headquartered in Hamilton, Canada.
Read More

Today's Range

Now: $21.55
Low: $21.55
High: $21.55

50 Day Range

MA: $21.50
Low: $21.38
High: $21.55

2 Week Range

Now: $21.55
Low: $2.31
High: $21.60

Volume

N/A

Average Volume

1,692,620 shs

Market Capitalization

$1.83 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
Top "Sleeping Giant" Crypto In The Market Now
From Crypto 101 Media   |   Ad
Top "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your financial future.
Click here to discover our #1 crypto pick before it's too late